Jojomarch ... If Rutherrin requires shelf certification, than this one would not qualify as our 2nd indication as it seems to be using Rutherrin.
Cervical cancer is using TLD-1433, for which we already have such certification.
Management has told us that the next indication PH1b will start when the PH2 NMIBC is well underway . That is a bit vague , now with the help of the research team on this bullboard ( yes you guys ) we know that extra compound has been produced . So they probably have their ducks lined up and could announce it early in 2020 . My money is on lung cancer but what about this one
Dr. Norman Marcon, MD, FRCP, Professor of Medicine in University of Toronto, Chief of Gastroenterology for St. Michael's Hospital, Toronto, Ontario stated, “This research was inspired by Theralase’s research into the role of the human glycoprotein Transferrin (“Tf”) and its associated cellular membrane Transferrin Receptor (“TfR”) CD71, that according to previous Theralase research is responsible for the targeted uptake of Theralase’s lead PDC, TLD-1433, by cancer cells. The aim of our research was to characterize CD71 expression in human samples of esophageal carcinomas and their precursor lesions. Remarkably, moderate to strong CD71 staining was seen almost universally (97.2%) in both SCC and adenocarcinoma. There was a significantly stronger expression of CD71 in HGD and carcinomas versus LGD and normal squamous mucosa tissues (p <0.02). This research is exciting as we now have a way to distinguish between LGD and HGD lesions. Moreover, CD71 is an important target for Rutherrin® (TLD-1433 combined with transferrin) and hence the development of an effective, targeted and highly personalised PDT destruction of HGD precursor lesions and cancers of the esophagus. This
latest research was presented and well received at the annual Canadian Academy of Pathology Meeting held in Quebec City, Quebec, Canada from July 7 to 10, 2018. Our therapeutic endoscopy group is looking forward to continuing our research with Theralase to clinically evaluate this technology in a Phase Ib clinical study aimed at the destruction of esophageal cancer.”